ERBB2 and breast cancer: ADC drugs have shown anti-cancer effectiveness against human epidermal growth factor receptor 2-positive (HER2+) breast cancers as well as anti-cancer effects on HER2-low and HER2-negative breast cancer and in triple-negative breast cancer (TNBC) patients [2].